Proteomic profiles of left atrial volume and its influence on response to spironolactone: Findings from the HOMAGE trial and STANISLAS cohort.
Biomarkers
Echocardiogram
Heart failure
Left atrial volume
Spironolactone
Journal
European journal of heart failure
ISSN: 1879-0844
Titre abrégé: Eur J Heart Fail
Pays: England
ID NLM: 100887595
Informations de publication
Date de publication:
25 Mar 2024
25 Mar 2024
Historique:
revised:
21
02
2024
received:
11
12
2023
accepted:
07
03
2024
medline:
26
3
2024
pubmed:
26
3
2024
entrez:
26
3
2024
Statut:
aheadofprint
Résumé
High left ventricular filling pressure increases left atrial volume and causes myocardial fibrosis, which may decrease with spironolactone. We studied clinical and proteomic characteristics associated with left atrial volume indexed by body surface area (LAVi), and whether LAVi influences the response to spironolactone on biomarker expression and clinical variables. In the HOMAGE trial, where people at risk of heart failure were randomized to spironolactone or control, we analysed 421 participants with available LAVi and 276 proteomic measurements (Olink) at baseline, month 1 and 9 (mean age 73 ± 6 years; women 26%; LAVi 32 ± 9 ml/m In individuals without heart failure, LAVi was associated with MMP-2, IGFBP-2 and NT-proBNP. Spironolactone reduced these biomarker concentrations as well as LAVi and PICP, irrespective of left atrial size.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : European Union Commission's Seventh Framework programme
Organisme : Netherlands Cardiovascular Research Initiative
Organisme : Dutch Heart Foundation, Dutch Cardiovascular AllianceCVON2016-Early HFPEF
ID : 2015-10
Organisme : CVON She-PREDICTS
ID : 2017-21
Organisme : FWO
ID : G091018N
Organisme : FWO
ID : G0B5930N
Organisme : Instituto de Salud Carlos III
Informations de copyright
© 2024 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Références
Kobayashi M, Girerd N, Ferreira JP, Kevin D, Huttin O, González A, et al. The association between markers of type I collagen synthesis and echocardiographic response to spironolactone in patients at risk of heart failure: Findings from the HOMAGE trial. Eur J Heart Fail 2022;24:1559–1568. https://doi.org/10.1002/ejhf.2579
Thomas L, Marwick TH, Popescu BA, Donal E, Badano LP. Left atrial structure and function, and left ventricular diastolic dysfunction: JACC state‐of‐the‐art review. J Am Coll Cardiol 2019;73:1961–1977. https://doi.org/10.1016/j.jacc.2019.01.059
Abhayaratna WP, Seward JB, Appleton CP, Douglas PS, Oh JK, Tajik AJ, et al. Left atrial size: Physiologic determinants and clinical applications. J Am Coll Cardiol 2006;47:2357–2363. https://doi.org/10.1016/j.jacc.2006.02.048
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2022;24:4–131. https://doi.org/10.1002/ejhf.2333
Baumgartner H, Hung J, Bermejo J, Chambers JB, Edvardsen T, Goldstein S, et al. Recommendations on the echocardiographic assessment of aortic valve stenosis: A focused update from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. J Am Soc Echocardiogr 2017;30:372–392. https://doi.org/10.1016/j.echo.2017.02.009
Inciardi RM, Claggett B, Minamisawa M, Shin SH, Selvaraj S, Gonçalves A, et al. Association of left atrial structure and function with heart failure in older adults. J Am Coll Cardiol 2022;79:1549–1561. https://doi.org/10.1016/j.jacc.2022.01.053
Shah AM, Claggett B, Sweitzer NK, Shah SJ, Anand IS, O'Meara E, et al. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: Findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circ Heart Fail 2014;7:740–751. https://doi.org/10.1161/CIRCHEARTFAILURE.114.001583
Pellicori P, Zhang J, Lukaschuk E, Joseph AC, Bourantas CV, Loh H, et al. Left atrial function measured by cardiac magnetic resonance imaging in patients with heart failure: Clinical associations and prognostic value. Eur Heart J 2015;36:733–742. https://doi.org/10.1093/eurheartj/ehu405
Inciardi RM, Bonelli A, Biering‐Sorensen T, Cameli M, Pagnesi M, Lombardi CM, et al. Left atrial disease and left atrial reverse remodelling across different stages of heart failure development and progression: A new target for prevention and treatment. Eur J Heart Fail 2022;24:959–975. https://doi.org/10.1002/ejhf.2562
Cleland JGF, Ferreira JP, Mariottoni B, Pellicori P, Cuthbert J, Verdonschot JAJ, et al.; HOMAGE Trial Committees and Investigators. The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: The Heart ‘OMics’ in AGEing (HOMAGE) randomized clinical trial. Eur Heart J 2021;42:684–696. https://doi.org/10.1093/eurheartj/ehaa758
Edelmann F, Wachter R, Schmidt AG, Kraigher‐Krainer E, Colantonio C, Kamke W, et al.; Aldo‐DHF Investigators. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: The Aldo‐DHF randomized controlled trial. JAMA 2013;309:781–791. https://doi.org/10.1001/jama.2013.905
Shah AM, Claggett B, Sweitzer NK, Shah SJ, Deswal A, Anand IS, et al. Prognostic importance of changes in cardiac structure and function in heart failure with preserved ejection fraction and the impact of spironolactone. Circ Heart Fail 2015;8:1052–1058. https://doi.org/10.1161/CIRCHEARTFAILURE.115.002249
Deswal A, Richardson P, Bozkurt B, Mann DL. Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM‐PEF). J Card Fail 2011;17:634–642. https://doi.org/10.1016/j.cardfail.2011.04.007
Kobayashi M, Ferreira MB, Costa RQ, Fonseca T, Oliveira JC, Marinho A, et al. Circulating biomarkers and cardiac structure and function in rheumatoid arthritis. Front Cardiovasc Med 2021;8:754784. https://doi.org/10.3389/fcvm.2021.754784
Hage C, Michaëlsson E, Linde C, Donal E, Daubert JC, Gan LM, et al. Inflammatory biomarkers predict heart failure severity and prognosis in patients with heart failure with preserved ejection fraction: A holistic proteomic approach. Circ Cardiovasc Genet 2017;10:e001633. https://doi.org/10.1161/CIRCGENETICS.116.001633
Ferreira JP, Girerd N, Bozec E, Mercklé L, Pizard A, Bouali S, et al. Cohort profile: Rationale and design of the fourth visit of the STANISLAS cohort: A familial longitudinal population‐based cohort from the Nancy region of France. Int J Epidemiol 2018;47:395–395j. https://doi.org/10.1093/ije/dyx240
Pellicori P, Ferreira JP, Mariottoni B, Brunner‐La Rocca HP, Ahmed FZ, Verdonschot J, et al. Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: Rationale, design and baseline characteristics of a proof‐of‐concept, randomised, precision‐medicine, prevention trial. The Heart OMics in AGing (HOMAGE) trial. Eur J Heart Fail 2020;22:1711–1723. https://doi.org/10.1002/ejhf.1716
Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006;145:247–254. https://doi.org/10.7326/0003‐4819‐145‐4‐200608150‐00004
Nagueh SF, Smiseth OA, Appleton CP, Byrd BF 3rd, Dokainish H, Edvardsen T, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2016;29:277–314. https://doi.org/10.1016/j.echo.2016.01.011
Rudski LG, Lai WW, Afilalo J, Hua L, Handschumacher MD, Chandrasekaran K, et al. Guidelines for the echocardiographic assessment of the right heart in adults: A report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr 2010;23:685–713. https://doi.org/10.1016/j.echo.2010.05.010
Lang RM, Badano LP, Mor‐Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2015;28:1–39.e14. https://doi.org/10.1016/j.echo.2014.10.003
Coiro S, Huttin O, Bozec E, Selton‐Suty C, Lamiral Z, Carluccio E, et al. Reproducibility of echocardiographic assessment of 2D‐derived longitudinal strain parameters in a population‐based study (the STANISLAS cohort study). Int J Cardiovasc Imaging 2017;33:1361–1369. https://doi.org/10.1007/s10554‐017‐1117‐z
Frikha Z, Girerd N, Huttin O, Courand PY, Bozec E, Olivier A, et al. Reproducibility in echocardiographic assessment of diastolic function in a population based study (the STANISLAS cohort study). PLoS One 2015;10:e0122336. https://doi.org/10.1371/journal.pone.0122336
López B, González A, Ravassa S, Beaumont J, Moreno MU, San José G, et al. Circulating biomarkers of myocardial fibrosis: The need for a reappraisal. J Am Coll Cardiol 2015;65:2449–2456. https://doi.org/10.1016/j.jacc.2015.04.026
Girerd N, Bresso E, Devignes MD, Rossignol P. Insulin‐like growth factor binding protein 2: A prognostic biomarker for heart failure hardly redundant with natriuretic peptides. Int J Cardiol 2020;300:252–254. https://doi.org/10.1016/j.ijcard.2019.11.100
Fabregat A, Korninger F, Viteri G, Sidiropoulos K, Marin‐Garcia P, Ping P, et al. Reactome graph database: Efficient access to complex pathway data. PLoS Comput Biol 2018;14:e1005968. https://doi.org/10.1371/journal.pcbi.1005968
Carbon S, Ireland A, Mungall CJ, Shu S, Marshall B, Lewis S. AmiGO: Online access to ontology and annotation data. Bioinformatics 2009;25:288–289. https://doi.org/10.1093/bioinformatics/btn615
Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res 2003;13:2498–2504. https://doi.org/10.1101/gr.1239303
Shah AM, Cikes M, Prasad N, Li G, Getchevski S, Claggett B, et al. Echocardiographic features of patients with heart failure and preserved left ventricular ejection fraction. J Am Coll Cardiol 2019;74:2858–2873. https://doi.org/10.1016/j.jacc.2019.09.063
Martignetti JA, Aqeel AA, Sewairi WA, Boumah CE, Kambouris M, Mayouf SA, et al. Mutation of the matrix metalloproteinase 2 gene (MMP2) causes a multicentric osteolysis and arthritis syndrome. Nat Genet 2001;28:261–265. https://doi.org/10.1038/90100
Lindsey ML, Goshorn DK, Squires CE, Escobar GP, Hendrick JW, Mingoia JT, et al. Age‐dependent changes in myocardial matrix metalloproteinase/tissue inhibitor of metalloproteinase profiles and fibroblast function. Cardiovasc Res 2005;66:410–419. https://doi.org/10.1016/j.cardiores.2004.11.029
Nagibin V, Egan Benova T, Viczenczova C, Viczenczova C, Szeiffova Bacova B, Dovinova I, et al. Ageing related down‐regulation of myocardial connexin‐43 and up‐regulation of MMP‐2 may predict propensity to atrial fibrillation in experimental animals. Physiol Res 2016;65:S91–s100. https://doi.org/10.33549/physiolres.933389
Zile MR, Jhund PS, Baicu CF, Claggett BL, Pieske B, Voors AA, et al.; Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction (PARAMOUNT) Investigators. Plasma biomarkers reflecting profibrotic processes in heart failure with a preserved ejection fraction: Data from the Prospective Comparison of ARNI with ARB on Management of Heart Failure with Preserved Ejection Fraction study. Circ Heart Fail 2016;9:e002551. https://doi.org/10.1161/CIRCHEARTFAILURE.115.002551
Buckley LF, Agha AM, Dorbala P, Claggett BL, Yu B, Hussain A, et al. MMP‐2 associates with incident heart failure and atrial fibrillation: The ARIC study. Circ Heart Fail 2023;16:e010849. https://doi.org/10.1161/CIRCHEARTFAILURE.123.010849
George J, Patal S, Wexler D, Roth A, Sheps D, Keren G. Circulating matrix metalloproteinase‐2 but not matrix metalloproteinase‐3, matrix metalloproteinase‐9, or tissue inhibitor of metalloproteinase‐1 predicts outcome in patients with congestive heart failure. Am Heart J 2005;150:484–487. https://doi.org/10.1016/j.ahj.2004.11.016
Peterson JT, Hallak H, Johnson L, Li H, O'Brien PM, Sliskovic DR, et al. Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure. Circulation 2001;103:2303–2309. https://doi.org/10.1161/01.cir.103.18.2303
Li H, Simon H, Bocan TM, Peterson JT. MMP/TIMP expression in spontaneously hypertensive heart failure rats: The effect of ACE‐ and MMP‐inhibition. Cardiovasc Res 2000;46:298–306. https://doi.org/10.1016/s0008‐6363(00)00028‐6
Hudson MP, Armstrong PW, Ruzyllo W, Brum J, Cusmano L, Krzeski P, et al. Effects of selective matrix metalloproteinase inhibitor (PG‐116800) to prevent ventricular remodeling after myocardial infarction: Results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial. J Am Coll Cardiol 2006;48:15–20. https://doi.org/10.1016/j.jacc.2006.02.055
Cittadini A, Grossman JD, Napoli R, Katz SE, Strömer H, Smith RJ, et al. Growth hormone attenuates early left ventricular remodeling and improves cardiac function in rats with large myocardial infarction. J Am Coll Cardiol 1997;29:1109–1116. https://doi.org/10.1016/s0735‐1097(97)00010‐7
Berry M, Galinier M, Delmas C, Fournier P, Desmoulin F, Turkieh A, Mischak H, Mullen W, Barutaut M, Eurlings LW, van Wijk S, Brunner‐la Rocca HP, Caubere C, Butler J, Roncalli J, Evaristi MF, Cohen‐Solal A, Seronde MF, Escamilla R, Ferrières J, Koukoui F, Smih F, Rouet P Proteomics analysis reveals IGFBP2 as a candidate diagnostic biomarker for heart failure. IJC Metab Endocr 2015;6:5–12. https://doi.org/10.1016/j.ijcme.2014.11.003
Barutaut M, Fournier P, Peacock WF, Evaristi MF, Caubère C, Turkieh A, et al. Insulin‐like growth factor binding protein 2 predicts mortality risk in heart failure. Int J Cardiol 2020;300:245–251. https://doi.org/10.1016/j.ijcard.2019.09.032
Ravassa S, Beaumont J, Cediel G, Lupón J, López B, Querejeta R, et al. Cardiorenal interaction and heart failure outcomes. A role for insulin‐like growth factor binding protein 2? Rev Esp Cardiol (Engl Ed) 2020;73:835–843. https://doi.org/10.1016/j.rec.2019.10.012
Zannad F, Alla F, Dousset B, Perez A, Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: Insights from the Randomized Aldactone Evaluation Study (RALES). RALES Investigators. Circulation 2000;102:2700–2706. https://doi.org/10.1161/01.cir.102.22.2700
Kurrelmeyer KM, Ashton Y, Xu J, Nagueh SF, Torre‐Amione G, Deswal A. Effects of spironolactone treatment in elderly women with heart failure and preserved left ventricular ejection fraction. J Card Fail 2014;20:560–568. https://doi.org/10.1016/j.cardfail.2014.05.010
Mak GJ, Ledwidge MT, Watson CJ, Phelan DM, Dawkins IR, Murphy NF, et al. Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone. J Am Coll Cardiol 2009;54:1674–1682. https://doi.org/10.1016/j.jacc.2009.08.021
Ferreira JP, Cleland JG, Girerd N, Bozec E, Rossignol P, Pellicori P, et al. Spironolactone effect on cardiac structure and function of patients with heart failure and preserved ejection fraction: A pooled analysis of three randomized trials. Eur J Heart Fail 2023;25:108–113. https://doi.org/10.1002/ejhf.2726
Gupta S, Matulevicius SA, Ayers CR, Berry JD, Patel PC, Markham DW, et al. Left atrial structure and function and clinical outcomes in the general population. Eur Heart J 2013;34:278–285. https://doi.org/10.1093/eurheartj/ehs188
Thomas L, Abhayaratna WP. Left atrial reverse remodeling: Mechanisms, evaluation, and clinical significance. JACC Cardiovasc Imaging 2017;10:65–77. https://doi.org/10.1016/j.jcmg.2016.11.003
Tousoulis D, Andreou I, Tentolouris C, Antoniades C, Papageorgiou N, Gounari P, et al. Comparative effects of rosuvastatin and allopurinol on circulating levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with chronic heart failure. Int J Cardiol 2010;145:438–443. https://doi.org/10.1016/j.ijcard.2009.05.051
Yu CM, Tipoe GL, Wing‐Hon Lai K, Lau CP. Effects of combination of angiotensin‐converting enzyme inhibitor and angiotensin receptor antagonist on inflammatory cellular infiltration and myocardial interstitial fibrosis after acute myocardial infarction. J Am Coll Cardiol 2001;38:1207–1215. https://doi.org/10.1016/s0735‐1097(01)01518‐2
Kobayashi M, Huttin O, Magnusson M, Ferreira JP, Bozec E, Huby AC, et al.; STANISLAS Study Investigators. Machine learning‐derived echocardiographic phenotypes predict heart failure incidence in asymptomatic individuals. JACC Cardiovasc Imaging 2022;15:193–208. https://doi.org/10.1016/j.jcmg.2021.07.004
Kobayashi M, Huttin O, Ferreira JP, Duarte K, González A, Heymans S, et al.; HOMAGE Trial Committees and Investigators. A machine learning‐derived echocardiographic algorithm identifies people at risk of heart failure with distinct cardiac structure, function, and response to spironolactone: Findings from the HOMAGE trial. Eur J Heart Fail 2023;25:1284–1289. https://doi.org/10.1002/ejhf.2859